Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,463.00    -8.00 (-0.54%)
Bid:
1,464.00
Ask:
1,466.00
Spread: 2.00 (0.137%)
Market Cap: £3.11b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

10 Apr 2018 14:34

RNS Number : 4612K
Hikma Pharmaceuticals Plc
10 April 2018
 

 

Hikma Pharmaceuticals PLC - EIP Awards

LONDON, 10 April 2018: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 10 April 2015 under the 2014 Executive Incentive Plan ("EIP") which was completed on10 April 2018. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the EIP is £nil.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

Bassam Kanaan

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 19,945

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

 

Khalid Nabilsi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Khalid Nabilsi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 14,165

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

Riad Mishlawi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Riad Mishlawi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 13,811

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

 

 

Majda Labadi

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Majda Labadi

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Shares acquired from vesting of the conditional awards on10 April 2018 under the EIP.

c)

Price(s) and volume(s)

Price(s): £nil

Volume(s): 10,089

d)

Aggregated information

N/A

e)

Date of the transaction

10 April 2018

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter SpeirsCompany Secretary, responsible for releasing this announcement+44 (0) 20 7399 2760

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBXGDSXXBBGIG
Date   Source Headline
11th Mar 20211:36 pmRNSHikma and GSK agree to cease potential acquisition
2nd Mar 20214:44 pmRNSDirector/PDMR Shareholding
25th Feb 20211:02 pmRNSDirector/PDMR Shareholding
25th Feb 20211:02 pmRNSDirector/PDMR Shareholding
25th Feb 20211:01 pmRNSDirector/PDMR Shareholding
25th Feb 20211:00 pmRNSDirector/PDMR Shareholding
25th Feb 20217:00 amRNSFinal Results
8th Feb 20212:55 pmRNSNotice of Results
26th Jan 20218:01 amRNSPotential Acquisition
15th Jan 20213:59 pmRNSHikma provides update on generic Advair Diskus®
13th Jan 20219:21 amRNSDirector/PDMR Shareholding
13th Jan 20219:14 amRNSDirector/PDMR Shareholding
18th Dec 202010:10 amRNSHolding(s) in Company
17th Dec 20205:30 pmRNSHikma launches generic Advair Diskus®
14th Dec 202012:57 pmRNSHolding(s) in Company
10th Dec 20204:00 pmRNSDirector/PDMR Shareholding
10th Dec 20203:51 pmRNSDirector/PDMR Shareholding
2nd Dec 20203:00 pmRNSTotal Voting Rights
2nd Dec 20201:05 pmRNSHolding(s) in Company
9th Nov 202011:38 amRNSHolding(s) in Company
5th Nov 202011:30 amRNSDirectorate Change
5th Nov 20207:00 amRNSHikma launches Icosapent Ethyl Capsules
5th Nov 20207:00 amRNSTrading Statement
2nd Nov 20201:20 pmRNSTotal Voting Rights
22nd Oct 20201:16 pmRNSNotice to Bondholders
8th Oct 20208:38 amRNSBlocklisting Application
1st Oct 202011:01 amRNSBlock listing Interim Review
22nd Sep 20207:00 amRNSHikma updates on ANDA for generic Advair Diskus®
3rd Sep 20203:15 pmRNSHikma receives favourable court ruling
2nd Sep 20209:30 amRNSTotal Voting Rights
7th Aug 20207:00 amRNSHalf-year Report
3rd Aug 20202:25 pmRNSTotal Voting Rights
16th Jul 202012:06 pmRNSNotice of Results
7th Jul 202012:48 pmRNSPublication of Offering Circular
25th Jun 20204:12 pmRNSHolding(s) in Company
25th Jun 20201:00 pmRNSDirectorate Change
23rd Jun 20205:30 pmRNSHikma Pharmaceuticals
23rd Jun 202011:39 amRNSHolding(s) in Company
23rd Jun 20207:00 amRNSTransaction in Own Shares
23rd Jun 20207:00 amRNSResult of placing in Hikma Pharmaceuticals PLC
22nd Jun 20205:13 pmRNSTransaction in Own Shares
22nd Jun 20205:09 pmRNSProposed Placing in Hikma Pharmaceuticals PLC
22nd Jun 202011:24 amRNSDirector/PDMR Shareholding
22nd Jun 202011:22 amRNSDirector/PDMR Shareholding
22nd Jun 202011:20 amRNSDirector/PDMR Shareholding
2nd Jun 20209:31 amRNSTotal Voting Rights
22nd May 20207:00 amRNSHikma receives FDA approval for generic Vascepa®
20th May 20203:42 pmRNSDirector/PDMR Shareholding
13th May 20201:28 pmRNSDirector/PDMR Shareholding
1st May 202011:30 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.